Cargando…

High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression

INTRODUCTION: Selenium (Se) is an essential trace element that exerts its effects mainly as the proteinogenic amino acid selenocysteine within a small set of selenoproteins. Among all family members, selenoprotein P (SELENOP) constitutes a particularly interesting protein as it serves as a biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackler, Julian, Demircan, Kamil, Chillon, Thilo Samson, Sun, Qian, Geisler, Nino, Schupp, Michael, Renko, Kostja, Schomburg, Lutz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816962/
https://www.ncbi.nlm.nih.gov/pubmed/36586222
http://dx.doi.org/10.1016/j.redox.2022.102592
_version_ 1784864658440585216
author Hackler, Julian
Demircan, Kamil
Chillon, Thilo Samson
Sun, Qian
Geisler, Nino
Schupp, Michael
Renko, Kostja
Schomburg, Lutz
author_facet Hackler, Julian
Demircan, Kamil
Chillon, Thilo Samson
Sun, Qian
Geisler, Nino
Schupp, Michael
Renko, Kostja
Schomburg, Lutz
author_sort Hackler, Julian
collection PubMed
description INTRODUCTION: Selenium (Se) is an essential trace element that exerts its effects mainly as the proteinogenic amino acid selenocysteine within a small set of selenoproteins. Among all family members, selenoprotein P (SELENOP) constitutes a particularly interesting protein as it serves as a biomarker and serum Se transporter from liver to privileged tissues. SELENOP expression is tightly regulated by dietary Se intake, inflammation, hypoxia and certain substances, but a systematic drug screening has hitherto not been performed. METHODS: A compound library of 1861 FDA approved clinically relevant drugs was systematically screened for interfering effects on SELENOP expression in HepG2 cells using a validated ELISA method. Dilution experiments were conducted to characterize dose-responses. A most potent SELENOP inhibitor was further characterized by RNA-seq analysis to assess effect-associated biochemical pathways. RESULTS: Applying a 2-fold change threshold, 236 modulators of SELENOP expression were identified. All initial hits were replicated as biological triplicates and analyzed for effects on cell viability. A set of 38 drugs suppressed SELENOP expression more than three-fold, among which were cancer drugs, immunosuppressants, anti-infectious drugs, nutritional supplements and others. Considering a 90% cell viability threshold, resveratrol, vidofludimus, and antimony potassium-tartrate were the most potent substances with suppressive effects on extracellular SELENOP concentrations. Resveratrol suppressed SELENOP levels dose-dependently in a concentration range from 0.8 μM to 50.0 μM, without affecting cell viability, along with strong effects on key genes controlling metabolic pathways and vesicle trafficking. CONCLUSION: The results highlight an unexpected direct effect of the plant stilbenoid resveratrol, known for its antioxidative and health-promoting effects, on the central Se transport protein. The suppressive effects on SELENOP may increase liver Se levels and intracellular selenoprotein expression, thereby conferring additional protection to hepatocytes at the expense of systemic Se transport. Further physiological effects from this interaction require analyses in vivo and by clinical studies.
format Online
Article
Text
id pubmed-9816962
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98169622023-01-07 High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression Hackler, Julian Demircan, Kamil Chillon, Thilo Samson Sun, Qian Geisler, Nino Schupp, Michael Renko, Kostja Schomburg, Lutz Redox Biol Research Paper INTRODUCTION: Selenium (Se) is an essential trace element that exerts its effects mainly as the proteinogenic amino acid selenocysteine within a small set of selenoproteins. Among all family members, selenoprotein P (SELENOP) constitutes a particularly interesting protein as it serves as a biomarker and serum Se transporter from liver to privileged tissues. SELENOP expression is tightly regulated by dietary Se intake, inflammation, hypoxia and certain substances, but a systematic drug screening has hitherto not been performed. METHODS: A compound library of 1861 FDA approved clinically relevant drugs was systematically screened for interfering effects on SELENOP expression in HepG2 cells using a validated ELISA method. Dilution experiments were conducted to characterize dose-responses. A most potent SELENOP inhibitor was further characterized by RNA-seq analysis to assess effect-associated biochemical pathways. RESULTS: Applying a 2-fold change threshold, 236 modulators of SELENOP expression were identified. All initial hits were replicated as biological triplicates and analyzed for effects on cell viability. A set of 38 drugs suppressed SELENOP expression more than three-fold, among which were cancer drugs, immunosuppressants, anti-infectious drugs, nutritional supplements and others. Considering a 90% cell viability threshold, resveratrol, vidofludimus, and antimony potassium-tartrate were the most potent substances with suppressive effects on extracellular SELENOP concentrations. Resveratrol suppressed SELENOP levels dose-dependently in a concentration range from 0.8 μM to 50.0 μM, without affecting cell viability, along with strong effects on key genes controlling metabolic pathways and vesicle trafficking. CONCLUSION: The results highlight an unexpected direct effect of the plant stilbenoid resveratrol, known for its antioxidative and health-promoting effects, on the central Se transport protein. The suppressive effects on SELENOP may increase liver Se levels and intracellular selenoprotein expression, thereby conferring additional protection to hepatocytes at the expense of systemic Se transport. Further physiological effects from this interaction require analyses in vivo and by clinical studies. Elsevier 2022-12-26 /pmc/articles/PMC9816962/ /pubmed/36586222 http://dx.doi.org/10.1016/j.redox.2022.102592 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Hackler, Julian
Demircan, Kamil
Chillon, Thilo Samson
Sun, Qian
Geisler, Nino
Schupp, Michael
Renko, Kostja
Schomburg, Lutz
High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
title High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
title_full High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
title_fullStr High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
title_full_unstemmed High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
title_short High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
title_sort high throughput drug screening identifies resveratrol as suppressor of hepatic selenop expression
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816962/
https://www.ncbi.nlm.nih.gov/pubmed/36586222
http://dx.doi.org/10.1016/j.redox.2022.102592
work_keys_str_mv AT hacklerjulian highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT demircankamil highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT chillonthilosamson highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT sunqian highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT geislernino highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT schuppmichael highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT renkokostja highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression
AT schomburglutz highthroughputdrugscreeningidentifiesresveratrolassuppressorofhepaticselenopexpression